Acurx Pharmaceuticals, Inc. (ACXP) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.06

From 52W high−84.39%

Volume51996.00

Market cap$5.66M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.06

From 52W high

−84.39%

Volume

51996.00

Market cap

$5.66M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.7x

P/E (TTM)

—

RSI (14)

34.2

MomentumView details →

1D Return

+1.47%

YTD Return

−57.83%

SummaryUpdated Jun 1, 2026

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Staten Island, New York. The company went public in June 2021 and focuses on developing novel antibiotics to treat serious bacterial infections. Acurx's primary focus is advancing its lead drug candidate, ibezapolstat, through clinical trials for treating Clostridium difficile infections, a potentially life-threatening condition that affects hundreds of thousands of patients annually.

Ask drillr about Acurx Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.7x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−92.08%

ROA (TTM)

−68.33%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+66.98%

FCF YoY

+24.25%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+69.76%

EBITDA YoY

—

MomentumView details →

1D Return

+1.47%

YTD Return

−57.83%

1Y Return

−79.61%

RSI (14)

34.2

vs 50D SMA

−17.61%

vs 200D SMA

−46.22%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

3.88x

Quick Ratio

3.88x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.53

EPS Surprise

−40.71%

Beats (12Q)

6/12

Next Q EPS Est

−$0.36

Avg Surprise (4Q)

−130991.83%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−7.51M

Op. CF (TTM)

−6.18M

Next earningsNov 12, 2026 →

Latest newsMore news →

Acurx Pharmaceuticals announced that it will discuss its third-quarter 2026 financial results on a conference call on November 12, 2026, at 8:00 a.m. ET.9d ago

Acurx Pharmaceuticals enrolled the first patient in its Phase 2 PATHFINDER clinical trial of ibezapolstat in patients with multiply-recurrent C. difficile infection.36d ago

Similar companies

Ainos, Inc.AIMD Evogene Ltd.EVGN Longeveron Inc.LGVN Instinct Bio Technical Co. Holdings Inc.BIOT Senti Biosciences, Inc.SNTI Skye Bioscience, Inc.SKYE Find similar companies →

Latest newsMore news →

Acurx Pharmaceuticals announced that it will discuss its third-quarter 2026 financial results on a conference call on November 12, 2026, at 8:00 a.m. ET.9d ago Acurx Pharmaceuticals enrolled the first patient in its Phase 2 PATHFINDER clinical trial of ibezapolstat in patients with multiply-recurrent C. difficile infection.36d ago